logo

Canadian Respiratory Journal

Canadian Respiratory Journal / 2019 / Article / Tab 2

Research Article

Prognostic Value of Concomitant Bronchiectasis in Newly Diagnosed Diffuse Panbronchiolitis Patients on a Maintenance Therapy with Macrolides

Table 2

Medications, therapeutic effects, and exacerbation frequencies in DPB subjects with and without bronchiectasis during follow-up.
Treatment and outcomeWhole group ()DPB with Bronchiectasis ()DPB without Bronchiectasis () value▲
Macrolide antibiotics   0.572
 Azithromycin179 (82.5)104 (80.6)75 (85.2) 
 Clarithromycin23 (10.6)15 (11.6)8 (9.1) 
 Erythromycin12 (5.5)7 (5.4)5 (5.7) 
 Roxithromycin3 (1.4)3 (2.3)0 (0) 
Regular ICS + LABA35 (16.1)18 (14.0)17 (19.3)0.291
Regular LAMA28 (12.9)18 (14.0)10 (11.4)0.576
Follow-up period (months)32.0 (18.5, 41.0)35.5 (16.0, 45.0)29.0 (21.0, 39.0)0.192
Exacerbation frequency (time/year)■0.5 (0, 1.5)0.7 (0, 1.6)0.3 (0, 1.3)0.048
Treatment efficacy   <0.001
 Healed36 (16.6)18 (20.5)18 (14.0) 
 Improved102 (47.0)53 (60.2)49 (38.0) 
 Unchanged39 (18.0)6 (6.8)33 (25.6) 
 Deteriorating32 (14.7)7 (8.0)25 (19.4) 
 Recurrent8 (3.7)4 (4.5)4 (3.1) 
Overall response   <0.001
 Responsive138 (63.6)67 (51.9)71 (80.7) 
 Unresponsive79 (36.4)62 (48.1)17 (19.3) 
Data are presented as median (interquartile range) or numbers (percentages). DPB: diffuse panbronchiolitis; ICS: inhaled corticosteroid; LABA: long-acting bronchial agonist; LAMA: long-acting muscarinic antagonist. ▲Comparison of DPB subjects with and without bronchiectasis. ■The exacerbation frequency (time/year) was defined as the number of exacerbation events/duration of follow-up (months) × 12.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.